Ryu Kanzaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ryu Kanzaki has a total of 234 co-authors. Here are the top co-authors by number of shared publications:
Masato Minami
Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Suita-City, Japan
34 shared publicationsYasushi Shintani
Department of General Thoracic Surgery Osaka University Graduate School of Medicine Suita Japan
32 shared publicationsMeinoshin Okumura
29 shared publicationsSoichiro Funaki
Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Suita-City, Japan
25 shared publicationsJiro Okami
Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka, Japan
20 shared publications- Yasushi Shintani
Department of General Thoracic Surgery The University of Osaka Graduate School of Medicine Suita Japan
18 shared publications
Latest Publications
- 6 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (10) , 9012
ASO Author Reflections: Reconsidering Surgical Indications for Clinical T4 Non-Small Cell Lung Cancer in the TNM 9th Edition Era
- 6 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (10) , 9012
ASO Author Reflections: Reconsidering Surgical Indications for Clinical T4 Non-Small Cell Lung Cancer in the TNM 9th Edition Era
- 15 June 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (9) , 1911-1918
Treatment strategies and outcomes in patients with synchronous multiple primary malignancies involving lung cancer
Synchronous multiple primary malignancies (sMPMs) involving lung cancer present complex clinical challenges requiring individualized treatment strategies. While surgical outcomes have been reported, data on long-term outcomes, including the development of new additional primary malignancies after surgery, remain limited. We retrospectively analyzed 85 patients with sMPMs involving lung cancer selected from 2820 patients who underwent pulmonary resection between 2008 and 2020. Surgical strategies, treatment sequence, perioperative outcomes, and long-term survival were evaluated. The incidence of new additional primary malignancies was assessed using person-time and competing risk analysis. Among the 85 patients, lung cancer was treated first in 30, the other malignancy first in 41, and simultaneous surgery was performed in 14. Lobectomy was the most common procedure (73%). Postoperative complications occurred in 22% of patients. The 5-year recurrence-free survival and overall survival rates were 63 and 69%, respectively. During 485.3 person-years of follow-up, 11 patients developed new additional primary malignancies, corresponding to an incidence rate of 22.7 per 1000 person-years. In competing risk analysis, the cumulative incidence was 6.0% at 5 years and 20.3% at 10 years after lung cancer surgery. Surgical treatment for lung cancer is feasible in selected patients with sMPMs. The occurrence of new additional primary malignancies should be recognized as a clinically relevant aspect of postoperative management.
- 15 June 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (9) , 1911-1918
Treatment strategies and outcomes in patients with synchronous multiple primary malignancies involving lung cancer
Synchronous multiple primary malignancies (sMPMs) involving lung cancer present complex clinical challenges requiring individualized treatment strategies. While surgical outcomes have been reported, data on long-term outcomes, including the development of new additional primary malignancies after surgery, remain limited. We retrospectively analyzed 85 patients with sMPMs involving lung cancer selected from 2820 patients who underwent pulmonary resection between 2008 and 2020. Surgical strategies, treatment sequence, perioperative outcomes, and long-term survival were evaluated. The incidence of new additional primary malignancies was assessed using person-time and competing risk analysis. Among the 85 patients, lung cancer was treated first in 30, the other malignancy first in 41, and simultaneous surgery was performed in 14. Lobectomy was the most common procedure (73%). Postoperative complications occurred in 22% of patients. The 5-year recurrence-free survival and overall survival rates were 63 and 69%, respectively. During 485.3 person-years of follow-up, 11 patients developed new additional primary malignancies, corresponding to an incidence rate of 22.7 per 1000 person-years. In competing risk analysis, the cumulative incidence was 6.0% at 5 years and 20.3% at 10 years after lung cancer surgery. Surgical treatment for lung cancer is feasible in selected patients with sMPMs. The occurrence of new additional primary malignancies should be recognized as a clinically relevant aspect of postoperative management.
- Open Access
- 4 May 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (5)
Mid-Term Outcomes of Titanium Plate Reconstruction for Lung Cancer Requiring Chest Wall Resection
Objectives: Chest wall resection for non-small cell lung cancer (NSCLC) with chest wall invasion is rare and technically demanding, requiring complete resection and durable reconstruction. Although titanium-based devices are increasingly used, NSCLC-specific outcome data remain limited. We evaluated short- and mid-term outcomes of titanium plate-based chest wall reconstruction in NSCLC. Methods: We retrospectively reviewed 16 consecutive patients who underwent en bloc pulmonary and chest wall resection with titanium plate reconstruction for NSCLC between 2013 and 2019. Indications included resection of ≥3 ribs or anticipated instability. Reconstruction used perforated titanium plates tailored to defect geometry. Postoperative complications, late reconstruction-related events, and oncologic outcomes were analysed. Results: Preoperative therapy was administered in 8 patients (50%), including chemoradiotherapy in 7. R0 resection was achieved in 94%. Defects were predominantly posterior, with reconstruction adjacent to the scapula in 12 patients (75%). Thirty-day postoperative complications occurred in 9 patients (56%), consisting predominantly of pulmonary events. Postoperative chemotherapy was given to 6 patients (38%). During a median follow-up of 24 months (mean 54 months), 2 late complications occurred: chest wall haematoma and empyema. Only 1 chest wall local recurrence was observed. No structural failure or scapular impingement occurred. Five-year recurrence-free and overall survival rates were 35% and 63%, respectively. Conclusions: Titanium plate-based chest wall reconstruction enables extensive en bloc resection for NSCLC with chest wall invasion while maintaining mid-term structural stability. With appropriate patient selection and follow-up, this technique provides acceptable mid-term outcomes with durable structural stability.
- 4 May 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (5)
Open AccessMid-Term Outcomes of Titanium Plate Reconstruction for Lung Cancer Requiring Chest Wall Resection
Objectives: Chest wall resection for non-small cell lung cancer (NSCLC) with chest wall invasion is rare and technically demanding, requiring complete resection and durable reconstruction. Although titanium-based devices are increasingly used, NSCLC-specific outcome data remain limited. We evaluated short- and mid-term outcomes of titanium plate-based chest wall reconstruction in NSCLC. Methods: We retrospectively reviewed 16 consecutive patients who underwent en bloc pulmonary and chest wall resection with titanium plate reconstruction for NSCLC between 2013 and 2019. Indications included resection of ≥3 ribs or anticipated instability. Reconstruction used perforated titanium plates tailored to defect geometry. Postoperative complications, late reconstruction-related events, and oncologic outcomes were analysed. Results: Preoperative therapy was administered in 8 patients (50%), including chemoradiotherapy in 7. R0 resection was achieved in 94%. Defects were predominantly posterior, with reconstruction adjacent to the scapula in 12 patients (75%). Thirty-day postoperative complications occurred in 9 patients (56%), consisting predominantly of pulmonary events. Postoperative chemotherapy was given to 6 patients (38%). During a median follow-up of 24 months (mean 54 months), 2 late complications occurred: chest wall haematoma and empyema. Only 1 chest wall local recurrence was observed. No structural failure or scapular impingement occurred. Five-year recurrence-free and overall survival rates were 35% and 63%, respectively. Conclusions: Titanium plate-based chest wall reconstruction enables extensive en bloc resection for NSCLC with chest wall invasion while maintaining mid-term structural stability. With appropriate patient selection and follow-up, this technique provides acceptable mid-term outcomes with durable structural stability.
- Open Access
- 20 April 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (4) , e70672
CD81 promotes proliferation and predicts survival in lung squamous cell carcinoma
- 20 April 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (4) , e70672
Open AccessCD81 promotes proliferation and predicts survival in lung squamous cell carcinoma
- Open Access
- 26 March 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (4)
Pulmonary Metastasectomy for Head and Neck Squamous Cell Carcinoma in the Modern Treatment Era
Objectives: Pulmonary metastasectomy (PM) has been a viable treatment option for metastatic head and neck squamous cell carcinoma (HNSCC). In recent years, advances in systemic therapy and multidisciplinary cancer management, including immune checkpoint inhibitors (ICIs), have changed the treatment landscape of advanced or recurrent head and neck cancer. Methods: We retrospectively reviewed 44 patients who underwent complete resection for pulmonary metastases from HNSCC between 2008 and 2021. To minimize the risk of including primary lung cancer, 8 patients were excluded based on predefined clinical criteria, resulting in a final cohort of 36 patients for analysis. Patients were divided into the early (2008-2016) and late (2017-2021) period groups. Relapse-free survival (RFS), overall survival (OS), and prognostic factors were assessed. Results: The 5-year RFS and OS for all patients were 41% and 67%, respectively. Postoperative chemotherapy was associated with better RFS, and age ≤65 years with better OS. ICIs were administered to 1 patient in the early period group and 7 in the late period group during the clinical course (P = .005). The 5-year RFS and OS were 42% vs 40% and 55% vs 87% in the early and late period groups, respectively. While RFS was comparable, OS tended to be better in the late period group, although the difference was not statistically significant. Conclusions: PM is associated with favourable long-term outcomes in patients with HNSCC. Given its potential for long-term survival and diagnostic value, PM remains an important treatment option for HNSCC in the modern treatment era.
- 26 March 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (4)
Open AccessPulmonary Metastasectomy for Head and Neck Squamous Cell Carcinoma in the Modern Treatment Era
Objectives: Pulmonary metastasectomy (PM) has been a viable treatment option for metastatic head and neck squamous cell carcinoma (HNSCC). In recent years, advances in systemic therapy and multidisciplinary cancer management, including immune checkpoint inhibitors (ICIs), have changed the treatment landscape of advanced or recurrent head and neck cancer. Methods: We retrospectively reviewed 44 patients who underwent complete resection for pulmonary metastases from HNSCC between 2008 and 2021. To minimize the risk of including primary lung cancer, 8 patients were excluded based on predefined clinical criteria, resulting in a final cohort of 36 patients for analysis. Patients were divided into the early (2008-2016) and late (2017-2021) period groups. Relapse-free survival (RFS), overall survival (OS), and prognostic factors were assessed. Results: The 5-year RFS and OS for all patients were 41% and 67%, respectively. Postoperative chemotherapy was associated with better RFS, and age ≤65 years with better OS. ICIs were administered to 1 patient in the early period group and 7 in the late period group during the clinical course (P = .005). The 5-year RFS and OS were 42% vs 40% and 55% vs 87% in the early and late period groups, respectively. While RFS was comparable, OS tended to be better in the late period group, although the difference was not statistically significant. Conclusions: PM is associated with favourable long-term outcomes in patients with HNSCC. Given its potential for long-term survival and diagnostic value, PM remains an important treatment option for HNSCC in the modern treatment era.
- 5 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1806-1816
Differential Diagnosis of Solitary Pulmonary Nodules in Postoperative Pancreatic Cancer Patients Using KRAS Gene Mutation Analysis
Solitary pulmonary nodules in postoperative pancreatic cancer patients pose a diagnostic challenge in distinguishing primary lung cancer (PLC) from pulmona
- 5 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1806-1816
Differential Diagnosis of Solitary Pulmonary Nodules in Postoperative Pancreatic Cancer Patients Using KRAS Gene Mutation Analysis
Solitary pulmonary nodules in postoperative pancreatic cancer patients pose a diagnostic challenge in distinguishing primary lung cancer (PLC) from pulmona
- Open Access
- 25 September 2025
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 40 (10)
Intraoperative Diaphragmatic Plication During Initial Surgery With Phrenic Nerve Resection
Objectives: Diaphragmatic palsy can result in respiratory failure, potentially alleviated by diaphragmatic plication. Nevertheless, the benefits of preventive plication during phrenic nerve resection remain uncertain. This study evaluated whether preventive plication during primary surgery involving phrenic nerve resection alleviate paradoxical diaphragmatic movement and pulmonary function loss. Methods: Among 24,527 surgeries for lung cancer or mediastinal tumours at 11 institutions, 142 involved phrenic nerve resections. Of these, 132 patients were retrospectively analysed. Diaphragmatic displacement and pulmonary function were assessed pre- and postoperatively. Displacement was quantified by measuring thoracic height on pre- and postoperative chest X-rays (D, D′). Diaphragmatic displacement ratio was defined as: DDR = (D′ − D)/D × 100. Results: Seventy patients (53%) underwent preventive diaphragmatic plication during the primary surgery; 62 (47%) did not. Differences were significant overall and more pronounced in those undergoing left lobectomy or more extensive resection. In this subgroup, plication was associated with a smaller change in DDR (−30.1 ± 7.7% vs −20.2 ± 7.7%, P = .002), and smaller declines in % predicted forced vital capacity (−30.5 ± 8.0% vs −16.8 ± 17.7%, P = .029) and forced expiratory volume in 1 second (−31.6 ± 11.0% vs −19.0 ± 14.5%, P = .046). Conclusions: In patients undergoing left lobectomy or more extensive resections involving phrenic nerve resection, intraoperative diaphragmatic plication may help preserve postoperative pulmonary function. However, due to the small sample size and limited generalizability, these findings should be interpreted cautiously.
- 25 September 2025
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 40 (10)
Open AccessIntraoperative Diaphragmatic Plication During Initial Surgery With Phrenic Nerve Resection
Objectives: Diaphragmatic palsy can result in respiratory failure, potentially alleviated by diaphragmatic plication. Nevertheless, the benefits of preventive plication during phrenic nerve resection remain uncertain. This study evaluated whether preventive plication during primary surgery involving phrenic nerve resection alleviate paradoxical diaphragmatic movement and pulmonary function loss. Methods: Among 24,527 surgeries for lung cancer or mediastinal tumours at 11 institutions, 142 involved phrenic nerve resections. Of these, 132 patients were retrospectively analysed. Diaphragmatic displacement and pulmonary function were assessed pre- and postoperatively. Displacement was quantified by measuring thoracic height on pre- and postoperative chest X-rays (D, D′). Diaphragmatic displacement ratio was defined as: DDR = (D′ − D)/D × 100. Results: Seventy patients (53%) underwent preventive diaphragmatic plication during the primary surgery; 62 (47%) did not. Differences were significant overall and more pronounced in those undergoing left lobectomy or more extensive resection. In this subgroup, plication was associated with a smaller change in DDR (−30.1 ± 7.7% vs −20.2 ± 7.7%, P = .002), and smaller declines in % predicted forced vital capacity (−30.5 ± 8.0% vs −16.8 ± 17.7%, P = .029) and forced expiratory volume in 1 second (−31.6 ± 11.0% vs −19.0 ± 14.5%, P = .046). Conclusions: In patients undergoing left lobectomy or more extensive resections involving phrenic nerve resection, intraoperative diaphragmatic plication may help preserve postoperative pulmonary function. However, due to the small sample size and limited generalizability, these findings should be interpreted cautiously.
- Open Access
- 1 January 2025
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 11 (1)
A Case of Spontaneous Regression of Primary Tumor after Adrenalectomy for Primary Lung Cancer with Synchronous Adrenal Metastasis
Adrenal metastasis from primary lung cancer is relatively common, occurring in approximately 5%-10% of clinical cases. Long-term survival can be achieved through surgical resection of adrenal metastases in addition to primary lesions. Spontaneous regression of cancer is defined as the partial shrinkage or complete disappearance of cancer following no treatment or treatment considered ineffective against cancer. Spontaneous regression of non-small cell lung cancer (NSCLC) is rare. Here, we describe a case of NSCLC with adrenal metastasis, in which the primary tumor exhibited spontaneous regression and was pathologically absent following surgical treatment of the metastatic lesion. A 59-year-old male patient was referred to our department with elevated carcinoembryonic antigen levels and an abnormal opacity on chest CT. Contrast-enhanced CT revealed a 2-cm lesion in the right upper lobe of the lung and a 4.5-cm mass in the right adrenal gland. Bronchoscopic biopsy confirmed non-small cell carcinoma (cT1bN0M1b, cStage IVA). As the adrenal metastasis was considered oligometastatic based on 18F-fluorodeoxyglucose PET/CT and head MRI, surgical resection of both the primary lung lesion and the adrenal metastasis was planned. Laparoscopic right adrenalectomy was performed, and histological examination confirmed adrenal metastasis from lung cancer. Postoperatively, no new metastases were detected, and CT demonstrated a reduction in the size of the primary lesion. Robot-assisted right upper lobectomy with lobe-specific nodal dissection was subsequently performed. Pathological examination revealed no malignant findings in the resected right upper lobe. The patient was discharged without complications and remains recurrence-free 5 months after surgery. This report presents a case of primary lung cancer with adrenal metastasis in which the primary tumor underwent spontaneous regression and was pathologically absent following surgical treatment of the metastasis.
- 1 January 2025
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 11 (1)
Open AccessA Case of Spontaneous Regression of Primary Tumor after Adrenalectomy for Primary Lung Cancer with Synchronous Adrenal Metastasis
Adrenal metastasis from primary lung cancer is relatively common, occurring in approximately 5%-10% of clinical cases. Long-term survival can be achieved through surgical resection of adrenal metastases in addition to primary lesions. Spontaneous regression of cancer is defined as the partial shrinkage or complete disappearance of cancer following no treatment or treatment considered ineffective against cancer. Spontaneous regression of non-small cell lung cancer (NSCLC) is rare. Here, we describe a case of NSCLC with adrenal metastasis, in which the primary tumor exhibited spontaneous regression and was pathologically absent following surgical treatment of the metastatic lesion. A 59-year-old male patient was referred to our department with elevated carcinoembryonic antigen levels and an abnormal opacity on chest CT. Contrast-enhanced CT revealed a 2-cm lesion in the right upper lobe of the lung and a 4.5-cm mass in the right adrenal gland. Bronchoscopic biopsy confirmed non-small cell carcinoma (cT1bN0M1b, cStage IVA). As the adrenal metastasis was considered oligometastatic based on 18F-fluorodeoxyglucose PET/CT and head MRI, surgical resection of both the primary lung lesion and the adrenal metastasis was planned. Laparoscopic right adrenalectomy was performed, and histological examination confirmed adrenal metastasis from lung cancer. Postoperatively, no new metastases were detected, and CT demonstrated a reduction in the size of the primary lesion. Robot-assisted right upper lobectomy with lobe-specific nodal dissection was subsequently performed. Pathological examination revealed no malignant findings in the resected right upper lobe. The patient was discharged without complications and remains recurrence-free 5 months after surgery. This report presents a case of primary lung cancer with adrenal metastasis in which the primary tumor underwent spontaneous regression and was pathologically absent following surgical treatment of the metastasis.
- Open Access
- 20 December 2024
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 19 (1) , 1-10
Long-term outcomes of surgical treatment of non-small cell lung cancer with oligometastatic disease involving only the brain in the era of PET/CT
The prognosis of patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) has been improving owing to advancements in imaging techniques and new treatment approaches such as tyrosine kinase inhibitors. This study aimed to investigate the long-term outcomes, including the clinical course after recurrence, of patients with synchronous oligometastatic NSCLC with only brain metastases, treated with bifocal treatment. We retrospectively analyzed 22 patients with clinical T1-4 and N0-1 NSCLC with synchronous brain metastases who were diagnosed by preoperative PET/CT and brain CT or MRI and underwent pulmonary resection for the primary site and surgery or radiation therapy for brain metastases at our institution from 2005 to 2019. The median follow-up period was 60 months. The 5-year recurrence-free survival rate and overall survival rates after pulmonary resection were 31.8% and 58.7%, respectively. In the univariate analysis, pathological N0 status was significantly associated with better recurrence-free survival, but not overall survival. The median survival after recurrence was 24 months. Aggressive brain treatment at sites of recurrence and the use of TKIs after recurrence have significantly prolonged prognosis. The long-term outcomes in patients with synchronous oligometastatic NSCLC with brain metastases who underwent bifocal treatment, including pulmonary resection, were favorable. In particular, bifocal treatment may provide a chance for cure in patients without lymph node involvement.
- 20 December 2024
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 19 (1) , 1-10
Open AccessLong-term outcomes of surgical treatment of non-small cell lung cancer with oligometastatic disease involving only the brain in the era of PET/CT
The prognosis of patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) has been improving owing to advancements in imaging techniques and new treatment approaches such as tyrosine kinase inhibitors. This study aimed to investigate the long-term outcomes, including the clinical course after recurrence, of patients with synchronous oligometastatic NSCLC with only brain metastases, treated with bifocal treatment. We retrospectively analyzed 22 patients with clinical T1-4 and N0-1 NSCLC with synchronous brain metastases who were diagnosed by preoperative PET/CT and brain CT or MRI and underwent pulmonary resection for the primary site and surgery or radiation therapy for brain metastases at our institution from 2005 to 2019. The median follow-up period was 60 months. The 5-year recurrence-free survival rate and overall survival rates after pulmonary resection were 31.8% and 58.7%, respectively. In the univariate analysis, pathological N0 status was significantly associated with better recurrence-free survival, but not overall survival. The median survival after recurrence was 24 months. Aggressive brain treatment at sites of recurrence and the use of TKIs after recurrence have significantly prolonged prognosis. The long-term outcomes in patients with synchronous oligometastatic NSCLC with brain metastases who underwent bifocal treatment, including pulmonary resection, were favorable. In particular, bifocal treatment may provide a chance for cure in patients without lymph node involvement.
- RetractionOpen Access
- 23 September 2024
- Published by Springer Nature in Nature Cell Biology
- Vol. 26 (10) , 1817
Retraction Note: CCM3 is a gatekeeper in focal adhesions regulating mechanotransduction and YAP/TAZ signalling
- 23 September 2024
- Published by Springer Nature in Nature Cell Biology
- Vol. 26 (10) , 1817
RetractionOpen AccessRetraction Note: CCM3 is a gatekeeper in focal adhesions regulating mechanotransduction and YAP/TAZ signalling